Sfoglia per AUTORE
GENOVA C
Collezione AOU San Luigi di Orbassano

  

Items : 15

2025
AOU San Luigi di Orbassano
AOU Novara

Wakelee H; Garassino M; Peters S; Takada K; Naqash AR; Torri V; Hejleh TA; Ferrara R; Aerts JGJV; Aboubakar Nana F; Dingemans AM; Biello F; Rogado J; Moliner L; Beninato T; Lo Russo G; Servetto A; Mezquita L; Gorría T; Minuti G; Bennati C; Tonini G; Cortinovis DL; Agustoni F; Majem M; Baena J; Macerelli M; Monnet I; O'Reilly D; et alii...

Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2024 May;202:114006. doi: 10.1016/j.ejca.2024.114006. Epub 2024 Mar 11.
2024
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Salerno F; Camerini A; Carta A; Follador A; Berardi R; Toschi L; Zoratto F; Cortinovis DL; Citarella F; Bulotta A; Rastelli F; Adamo V; Guida A; Manzo A; Cecere FL; Belluomini L; Roca E; Pasello G; Cerea G; Montrone M; Delcuratolo MD; Passiglia F; Guaitoli G; Bertolini F; Genova C; Caliman E; Mazzoni F; Siringo M; Gelibter A; et alii...

The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2024 May;191:107787. doi: 10.1016/j.lungcan.2024.107787. Epub 2024 Apr 5.
2024
AOU San Luigi di Orbassano

Malapelle U; Passiglia F; Pepe F; Pisapia P; Lucia Reale M; Cortinovis D; Fraggetta F; Galetta D; Garbo E; Graziano P; Pagni F; Pasello G; Piovano P; Pilotto S; Tiseo M; Genova C; Righi L; Troncone G; Novello S;

Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2024 Jan;187:107444. doi: 10.1016/j.lungcan.2023.107444. Epub 2023 Dec 15.
2024
ASL Alessandria
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Malapelle U; Novello S; Garbo E; Agustoni F; Gori S; Grisanti S; Catania C; Buffoni L; Buosi R; Brambilla M; Vavalà T; Scotti V; Carta A; Cerea G; Tiseo M; Delmonte A; Russo A; Cortinovis D; Chiari R; Metro G; Citarella F; Genova C; Roca E; Pilotto S; Bria E; Pelizzari G; Sini C; Galetta D; Bulotta A; et alii...

Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2024 Jan;19(1):166-172. doi: 10.1016/j.jtho.2023.08.004. Epub 2023 Aug 9.
2024
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Planchard D; Besse B; Novello S; Barlesi F; Le Péchoux C; Facchinetti F; Aldea M; Genova C; Bironzo P; Di Maio M; Remon J; Tagliamento M; Tagliamento M; Di Maio M; Remon J; Bironzo P; Genova C; Facchinetti F; Aldea M; Le Péchoux C; Novello S; Barlesi F; Besse B; Planchard D;

Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab. in Clinical and experimental medicine / Clin Exp Med. 2024 Aug 6;24(1):182. doi: 10.1007/s10238-024-01427-8.
2024
AOU San Luigi di Orbassano
AOU Novara

Gil-Bazo I; Baraibar I; Biello F; Rivoltini L; Chiari R; Baglivo S; Metro G; Passiglia F; Barletta G; Ludovini V; Rijavec E; Alama A; Dellepiane C; Dal Bello MG; Zullo L; Tagliamento M; Longo L; Vanni I; Rossi G; Ostano P; Santamaria S; Guana F; Chiorino G; Marconi S; Genova C; Novello S; Grossi F; Coco S;

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.
2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Russo A; Porzio G; Tiseo M; Russano M; Ficorella C; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Metro G; Migliorino MR; Passiglia F; Ricciardi S; Zoratto F; Pecci F; Di Marino P; Mansueto G; De Tursi M; Tuzi A; Gori S; Della Gravara L; Macerelli M; Rastelli F; Chiari R; Gelibter A; Marchetti P; Antonuzzo L; Mazzoni F; et alii...

Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP). in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2022 Dec;174:118-124. doi: 10.1016/j.lungcan.2022.11.005. Epub 2022 Nov 9.
2022
AOU San Luigi di Orbassano

Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F;

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.
2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Addeo A; Friedlaender A; Banna GL; Di Maio M; Spinelli GP; Russo A; Adamo V; De Filippis M; Metro G; Simona C; Natalizio S; Migliorino MR; Landi L; Ricciardi S; Buti S; Minuti G; Nigro O; Cantini L; Bracarda S; Citarella F; Russano M; Filetti M; Zoratto F; Gori S; De Tursi M; Mansueto G; Rocco D; et alii...

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.
2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Cortellini A; Mazzaschi G; Tiseo M; Pinato DJ; Carmisciano L; Ficorella C; Porzio G; Cannita K; Friedlaender A; Addeo A; Banna GL; Spinelli GP; Adamo V; Russo A; Olmetto E; Metro G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Minuti G; Tuzi A; Bisonni R; Follador A; Gelibter A; Siringo M; Signorelli D; De Toma A; Garassino MC; et alii...

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Porzio G; Cannita K; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Russo A; Adamo V; Metro G; Bironzo P; Passiglia F; Ricciardi S; Migliorino MR; Landi L; Minuti G; Tuzi A; Bordi P; Russano M; Cantini L; Santini D; Citarella F; Zoratto F; Filetti M; Mansueto G; Di Marino P; Grassadonia A; Inno A; et alii...

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ? 50%: a multicenter study with external validation. in Journal for immunotherapy of cancer / J Immunother Cancer. 2020 Oct;8(2):e001403. doi: 10.1136/jitc-2020-001403.
2020
AOU San Luigi di Orbassano

Cortellini A; Ricciuti B; Tiseo M; Bria E; Banna GL; Aerts JG; Barbieri F; Giusti R; Cortinovis DL; Migliorino MR; Catino A; Passiglia F; Torniai M; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Rastelli F; Chiari R; Rocco D; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Grossi F; et alii...

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ? 50% and Their Relationship With Clinical Outcomes. in Clinical lung cancer / Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21.
2020
AOU San Luigi di Orbassano

Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; et alii...

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ??50. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May
2020
AOU San Luigi di Orbassano

Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; et alii...

NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer. in The oncologist / Oncologist. 2018 Oct;23(10):1133-e112. doi: 10.1634/theoncologist.2018-0292. Epub 2018 Aug 3.
2018
AOU San Luigi di Orbassano

Gregorc V; Cavina R; Novello S; Grossi F; Lazzari C; Capelletto E; Genova C; Salini G; Lambiase A; Santoro A;